Clinical Approach to Heavy Menstrual Bleeding
Comprehensive Practical Framework1. Symptom Overview
Understanding the clinical significance and classification of heavy menstrual bleeding
Heavy menstrual bleeding (HMB) is one of the most common gynecological complaints, affecting approximately 10-30% of reproductive-age women worldwide. It accounts for nearly 20% of all gynecology outpatient visits and is the leading indication for hysterectomy. The condition significantly impacts quality of life, work productivity, and healthcare costs, with affected women experiencing twice the rate of work absenteeism compared to those with normal menstruation. Importantly, up to 50% of women with heavy menstrual bleeding will develop iron deficiency anemia.
Definition
Heavy menstrual bleeding is defined as excessive menstrual blood loss that interferes with a woman’s physical, social, emotional, or material quality of life. The traditional quantitative definition of blood loss greater than 80 mL per cycle has been largely replaced by this patient-centered definition, as clinical measurement of blood loss is impractical and subjective experience better guides treatment decisions. The term “heavy menstrual bleeding” has replaced the older term “menorrhagia” in modern nomenclature.
Classification by Duration and Pattern
| Category | Duration/Pattern | Common Causes | Clinical Significance |
|---|---|---|---|
| Acute Heavy Menstrual Bleeding | Single episode requiring immediate intervention | Pregnancy complications, coagulopathy, trauma, acute anovulation | Requires urgent evaluation; may need emergency hemostasis and transfusion |
| Chronic Heavy Menstrual Bleeding | Present for most of the previous 6 months | Fibroids, adenomyosis, endometrial polyps, ovulatory dysfunction | Systematic workup indicated; risk of iron deficiency anemia |
| Intermenstrual Bleeding | Bleeding between clearly defined menstrual periods | Cervical lesions, endometrial polyps, hormonal contraception | Must exclude cervical and endometrial pathology |
The PALM-COEIN Classification System
The International Federation of Gynecology and Obstetrics (FIGO) developed the PALM-COEIN classification system to standardize the categorization of abnormal uterine bleeding causes. This system divides etiologies into structural causes (PALM) that can be measured visually or with imaging, and non-structural causes (COEIN) that are diagnosed through history and exclusion.
PALM — Structural Causes
P — Polyp (endometrial or cervical)
A — Adenomyosis
L — Leiomyoma (fibroids)
M — Malignancy and hyperplasia
COEIN — Non-Structural Causes
C — Coagulopathy
O — Ovulatory dysfunction
E — Endometrial causes
I — Iatrogenic
N — Not otherwise classified
Classification by Bleeding Characteristics
| Pattern | Description | Suggests |
|---|---|---|
| Regular heavy bleeding | Heavy flow occurring at predictable intervals (21-35 days) | Structural causes: fibroids, adenomyosis, polyps; coagulopathy |
| Irregular heavy bleeding | Unpredictable timing with variable flow | Ovulatory dysfunction, endometrial hyperplasia, malignancy |
| Prolonged bleeding | Bleeding duration greater than 8 days per cycle | Submucosal fibroids, adenomyosis, coagulopathy |
| Flooding and clotting | Passing clots greater than 2.5 cm; soaking through protection hourly | Severe bleeding regardless of cause; higher likelihood of anemia |
| Postcoital bleeding | Bleeding triggered by intercourse | Cervical lesions (polyps, ectropion, malignancy), vaginal lesions |
Quantifying Menstrual Blood Loss
| Assessment Method | How It Works | Clinical Utility |
|---|---|---|
| Pictorial Blood Assessment Chart (PBAC) | Patient records number and saturation of pads/tampons; score calculated | Score greater than 100 correlates with blood loss greater than 80 mL; useful for monitoring treatment response |
| Number of products used | Count of pads or tampons used per day and per cycle | Greater than 21 products per cycle suggests heavy bleeding; simple to track |
| Subjective assessment | Patient’s perception of bleeding relative to normal and impact on life | Most practical; aligns with modern patient-centered definition |
Key Concept: While structural causes (PALM) account for approximately 50% of cases of heavy menstrual bleeding in reproductive-age women, non-structural causes (COEIN) are equally important and often overlooked. Notably, up to 20% of adolescents presenting with heavy menstrual bleeding will have an underlying bleeding disorder, and multiple etiologies may coexist in the same patient.
Impact on Quality of Life
Physical Impact
Iron deficiency anemia (up to 50% of affected women), fatigue, shortness of breath, palpitations, reduced exercise tolerance
Social Impact
Activity restriction, avoidance of social events, limitations on clothing choices, impact on sexual intimacy
Economic Impact
Work absenteeism (estimated 1.5 days per month), cost of menstrual products, healthcare expenditure
2. Pathophysiology and Mechanisms
Understanding the underlying mechanisms of heavy menstrual bleeding
Normal menstruation is a carefully orchestrated process involving cyclical endometrial growth, decidualization, and controlled shedding with precise hemostatic mechanisms. Heavy menstrual bleeding occurs when there is disruption of the hormonal regulation of the menstrual cycle, abnormalities in the local endometrial hemostatic mechanisms, structural lesions that increase endometrial surface area or vascularity, or systemic coagulation defects. Understanding these mechanisms is essential for targeted therapy.
The Normal Menstrual Cycle
| Phase | Hormonal Changes | Endometrial Changes |
|---|---|---|
| Proliferative Phase | Rising estrogen from developing follicle | Endometrial regeneration and thickening; spiral artery development |
| Secretory Phase | Progesterone from corpus luteum; estrogen maintained | Glandular secretion; stromal decidualization; vascular maturation |
| Menstruation | Withdrawal of estrogen and progesterone | Vasoconstriction, ischemia, tissue breakdown, controlled shedding |
Endometrial Hemostatic Mechanisms
Vasoconstriction
Mechanism: Spiral arteries constrict in response to progesterone withdrawal and local prostaglandins
Key mediators: Endothelin-1, prostaglandin F2α
Clinical relevance: Impaired vasoconstriction leads to prolonged bleeding
Platelet Aggregation
Mechanism: Platelets aggregate at sites of vascular injury in the shedding endometrium
Key mediators: Thromboxane A2, von Willebrand factor
Clinical relevance: Platelet disorders cause heavy bleeding despite normal cycle
Fibrinolysis Regulation
Mechanism: Balance between plasminogen activators and inhibitors
Key mediators: Tissue plasminogen activator, plasminogen activator inhibitor-1
Clinical relevance: Excessive fibrinolysis increases menstrual blood loss
Mechanisms by PALM-COEIN Category
| Condition | Mechanism | Treatment Implication |
|---|---|---|
| Polyps (endometrial) | Localized overgrowths with fragile surface vessels that bleed easily; may interfere with normal endometrial shedding | Hysteroscopic resection is curative; hormonal therapy alone rarely effective |
| Adenomyosis | Ectopic endometrial tissue within myometrium causes enlarged uterus with impaired contractility; increased surface area and abnormal vasculature | Levonorgestrel intrauterine system effective; GnRH agonists provide temporary relief; hysterectomy definitive |
| Leiomyoma (fibroids) | Submucosal fibroids distort cavity, increase surface area, and have abnormal vasculature; intramural fibroids impair uterine contractility | Location determines impact; submucosal fibroids most likely to cause bleeding; surgical removal often needed |
| Malignancy and hyperplasia | Endometrial hyperplasia results from unopposed estrogen; abnormal vasculature and fragile tissue; irregular shedding | Histological diagnosis essential; progestins for hyperplasia without atypia; surgery for malignancy |
| Coagulopathy | Defective platelet function or coagulation cascade impairs normal hemostasis at menstruation; von Willebrand disease most common | Tranexamic acid, desmopressin (for von Willebrand disease), factor replacement; hormonal suppression |
| Ovulatory dysfunction | Anovulation leads to unopposed estrogen, irregular endometrial proliferation, and unpredictable heavy bleeding when finally shed | Progestins to regulate cycle; combined hormonal contraception; address underlying cause (polycystic ovary syndrome, thyroid) |
| Endometrial causes | Primary disorders of endometrial hemostasis: increased fibrinolysis, reduced vasoconstriction, altered prostaglandin balance | Tranexamic acid (antifibrinolytic); nonsteroidal anti-inflammatory drugs (reduce prostaglandins); levonorgestrel intrauterine system |
| Iatrogenic | Anticoagulants impair hemostasis; copper intrauterine device increases prostaglandins and surface area; hormonal contraception breakthrough | Review and modify causative medications; consider alternative contraception |
Role of Prostaglandins
Prostaglandins play a crucial role in regulating menstrual blood loss through effects on vasoconstriction, platelet function, and myometrial contractility. The balance between vasoconstrictive prostaglandins (prostaglandin F2α, thromboxane A2) and vasodilatory prostaglandins (prostaglandin E2, prostacyclin) determines the degree of bleeding.
| Prostaglandin | Effect | Clinical Relevance |
|---|---|---|
| Prostaglandin F2α | Vasoconstriction; myometrial contraction | Reduced in women with heavy menstrual bleeding; explains efficacy of NSAIDs |
| Prostaglandin E2 | Vasodilation; inhibits platelet aggregation | Elevated in heavy menstrual bleeding; increases with copper intrauterine device |
| Thromboxane A2 | Vasoconstriction; platelet aggregation | Promotes hemostasis; reduced ratio to prostacyclin in heavy bleeding |
| Prostacyclin (PGI2) | Vasodilation; inhibits platelet aggregation | Elevated in heavy menstrual bleeding; counteracts hemostatic mechanisms |
Often Overlooked Mechanism
Primary endometrial hemostatic dysfunction — In many women with heavy menstrual bleeding and no structural abnormality, the underlying problem is disordered local endometrial hemostasis. These women have increased tissue plasminogen activator activity (excessive fibrinolysis), reduced endothelin-1 (impaired vasoconstriction), and altered prostaglandin balance. This explains why tranexamic acid (an antifibrinolytic) and nonsteroidal anti-inflammatory drugs (which alter prostaglandin synthesis) are effective even when no identifiable pathology exists. This category is classified as “E” (Endometrial) in the PALM-COEIN system.
Fibroid Location and Bleeding Risk
Not all fibroids cause heavy menstrual bleeding. The location of fibroids relative to the endometrial cavity determines their impact on menstrual blood loss.
| Fibroid Type | Location | Impact on Bleeding | FIGO Subclassification |
|---|---|---|---|
| Submucosal | Distorts or protrudes into endometrial cavity | High — most likely to cause heavy bleeding; increased surface area and abnormal vasculature | Types 0, 1, 2 |
| Intramural | Within myometrial wall | Variable — may impair uterine contractility if large; less direct effect on bleeding | Types 3, 4, 5 |
| Subserosal | Protrudes from serosal surface | Low — rarely causes heavy menstrual bleeding; may cause pressure symptoms | Types 6, 7 |
The Pathophysiology of Anovulatory Bleeding
Why anovulation causes heavy irregular bleeding:
- Continuous estrogen stimulation: Without ovulation, no corpus luteum forms and progesterone is not produced
- Endometrial proliferation: Estrogen causes the endometrium to thicken progressively
- Unstable endometrium: Without progesterone-induced decidualization, the endometrium becomes fragile
- Irregular shedding: The thickened, unstable endometrium sheds unpredictably and often heavily
- Hyperplasia risk: Prolonged unopposed estrogen increases the risk of endometrial hyperplasia and malignancy
3. History Taking
A comprehensive approach to eliciting the heavy menstrual bleeding history
Red Flags — Require Urgent Evaluation
- Hemodynamic instability — Tachycardia, hypotension, syncope; suggests acute severe blood loss
- Postmenopausal bleeding — Any bleeding after 12 months of amenorrhea; must exclude malignancy
- Intermenstrual bleeding in women over 45 — Increased risk of endometrial pathology
- Postcoital bleeding — Must exclude cervical malignancy
- Symptoms of severe anemia — Chest pain, dyspnea at rest, confusion
- Known or suspected pregnancy with bleeding — Ectopic pregnancy, miscarriage
Systematic History: The “HEAVY” Approach
Use the mnemonic “HEAVY” to ensure comprehensive history taking for menstrual bleeding:
- H — How much and how long?: Quantify blood loss (pads/tampons per day, clots, flooding), duration of bleeding, and cycle length
- E — Evolution and pattern: When did heavy bleeding start? Has it changed? Regular or irregular cycles? Intermenstrual or postcoital bleeding?
- A — Associated symptoms: Dysmenorrhea, pelvic pain, pressure symptoms, fatigue, bruising, nosebleeds, family history of bleeding disorders
- V — Vital background: Obstetric history, contraception use, medications (especially anticoagulants), sexual history, cervical screening status
- Y — Your life impact: Effect on work, social activities, relationships, and quality of life; what is the patient hoping to achieve?
Quantifying Menstrual Blood Loss
| Question | What to Ask | Significance |
|---|---|---|
| Products used | “How many pads or tampons do you use on your heaviest day? Per cycle?” | Greater than 21 products per cycle suggests heavy bleeding; changing hourly suggests severe bleeding |
| Saturation | “Are your pads or tampons fully soaked, or only partially?” | Fully soaked products indicate heavier loss; important for PBAC scoring |
| Clots | “Do you pass blood clots? How large are they?” | Clots greater than 2.5 cm (larger than a 10-cent coin) indicate heavy bleeding |
| Flooding | “Do you ever bleed through your clothes or bedding despite using protection?” | Flooding strongly suggests heavy menstrual bleeding; significant quality of life impact |
| Duration | “How many days does your period last?” | Greater than 8 days is prolonged; may indicate structural pathology or coagulopathy |
| Double protection | “Do you need to use a pad and tampon together?” | Need for double protection indicates heavy flow |
Targeted Questions by Suspected Cause
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| Uterine fibroids (leiomyomas) | Regular heavy periods, pelvic pressure, urinary frequency, constipation | “Do you feel pressure in your pelvis, or need to urinate frequently? Have you noticed your abdomen getting bigger?” |
| Adenomyosis | Heavy painful periods, pain worsening over years, dyspareunia | “Are your periods painful as well as heavy? Has the pain gotten worse over time? Do you have pain during intercourse?” |
| Endometrial polyps | Intermenstrual bleeding, postcoital bleeding, irregular pattern | “Do you have any bleeding between your periods or after intercourse?” |
| Ovulatory dysfunction | Irregular cycles, varying cycle length, obesity, hirsutism, acne | “Are your periods regular or unpredictable? How much does your cycle length vary? Do you have excess facial or body hair?” |
| Coagulopathy | Heavy periods since menarche, bleeding with dental work, easy bruising, family history | “Have your periods always been heavy since they started? Do you bruise easily? Have you ever had prolonged bleeding after dental work or surgery? Does anyone in your family have a bleeding disorder?” |
| Endometrial hyperplasia or malignancy | Postmenopausal bleeding, irregular bleeding over 45 years, obesity, diabetes, unopposed estrogen | “Have you had any bleeding after your menopause? Have you ever taken hormone replacement therapy without progesterone?” |
| Thyroid dysfunction | Menstrual changes with weight changes, fatigue, temperature intolerance, skin or hair changes | “Have you noticed changes in your weight, energy levels, or sensitivity to temperature? Any skin or hair changes?” |
Screening for Bleeding Disorders
When to Suspect an Underlying Coagulopathy
Up to 20% of adolescents and 10-15% of adults with heavy menstrual bleeding have an underlying bleeding disorder. Screen if any of the following are present:
- Heavy menstrual bleeding since menarche
- Personal history of: postpartum hemorrhage, surgical bleeding, bleeding with dental procedures
- Family history of bleeding disorder
- Easy bruising (especially without known trauma)
- Frequent nosebleeds (especially lasting more than 10 minutes)
- Bleeding gums
Medication and Contraceptive History
Medications That Cause or Worsen Heavy Bleeding
- Anticoagulants — Warfarin, direct oral anticoagulants (rivaroxaban, apixaban), heparin
- Antiplatelet agents — Aspirin, clopidogrel, prasugrel
- Copper intrauterine device — Increases prostaglandins and menstrual blood loss by 20-50%
- Selective serotonin reuptake inhibitors (SSRIs) — Impair platelet function
- Corticosteroids — Long-term use affects hemostasis
- Tamoxifen — Associated with endometrial polyps and hyperplasia
- Herbal supplements — Ginkgo, garlic, ginseng, fish oil may increase bleeding
Contraceptive History
- Current method — Type, duration of use, compliance
- Copper intrauterine device — Common cause of increased bleeding
- Hormonal contraception — Usually reduces bleeding; breakthrough bleeding in first 3 months is common
- Progestogen-only methods — Irregular bleeding is common, especially initially
- Recent discontinuation — Withdrawal bleeding may be heavy
- Future fertility desires — Critical for treatment planning
Reproductive and Obstetric History
| Area | What to Ask | Why It Matters |
|---|---|---|
| Menarche | Age of first period; were periods always heavy? | Heavy bleeding since menarche suggests coagulopathy or structural abnormality |
| Pregnancy status | Possibility of current pregnancy; last menstrual period | Must exclude pregnancy before investigation or treatment |
| Obstetric history | Number of pregnancies, deliveries, miscarriages; postpartum hemorrhage | Postpartum hemorrhage suggests coagulopathy; parity affects fibroid risk |
| Future fertility | Does she wish to conceive in the future? | Guides treatment options; some treatments affect fertility |
| Cervical screening | Date of last cervical smear; any abnormal results | Must be current before invasive procedures; identifies cervical pathology risk |
| Menopause status | Perimenopausal symptoms; date of last period if postmenopausal | Postmenopausal bleeding requires urgent investigation for malignancy |
Quality of Life Assessment
Understanding Impact: The modern definition of heavy menstrual bleeding is centered on quality of life impact. Ask about:
- Work or school absenteeism due to periods
- Social activities avoided during menstruation
- Anxiety about bleeding through clothes
- Impact on intimate relationships
- Restrictions on exercise or physical activity
- Sleep disturbance due to bleeding
- Financial burden of menstrual products
- Symptoms of anemia: fatigue, breathlessness, palpitations
4. Physical Examination
A systematic approach for evaluating heavy menstrual bleeding
Systematic Framework: Use a “General to Specific” approach — begin with general assessment and vital signs, then proceed to abdominal examination, and finally pelvic examination. A chaperone should be offered for all intimate examinations.
General Inspection
- Pallor — Conjunctival, palmar, and mucosal pallor suggesting anemia
- Body habitus — Obesity (associated with anovulation, polycystic ovary syndrome, endometrial hyperplasia); underweight (hypothalamic dysfunction)
- Hirsutism and acne — Signs of androgen excess suggesting polycystic ovary syndrome
- Bruising — Easy bruising without obvious cause suggesting coagulopathy
- Skin changes — Dry skin and hair loss (hypothyroidism); warm moist skin (hyperthyroidism)
- Acanthosis nigricans — Dark velvety patches in skin folds indicating insulin resistance
Vital Signs
| Vital Sign | What to Look For | Clinical Significance |
|---|---|---|
| Heart Rate | Tachycardia (greater than 100 beats per minute at rest) | May indicate anemia or acute blood loss; postural increase suggests hypovolemia |
| Blood Pressure | Hypotension; postural drop greater than 20 mmHg systolic | Suggests significant acute blood loss requiring urgent intervention |
| Respiratory Rate | Tachypnea at rest | May indicate severe anemia with compensatory response |
| Temperature | Fever | Suggests infection; consider pelvic inflammatory disease or endometritis |
| Body Mass Index | Calculate from height and weight | Obesity is a risk factor for anovulation, polycystic ovary syndrome, and endometrial hyperplasia |
Signs of Anemia
Examine For
- Conjunctival pallor (most reliable sign)
- Palmar crease pallor
- Oral mucosal pallor
- Nail bed pallor
- Koilonychia (spoon-shaped nails) — iron deficiency
- Angular cheilitis — iron deficiency
- Glossitis — smooth, red tongue
Cardiovascular Signs of Severe Anemia
- Tachycardia at rest
- Hyperdynamic precordium
- Flow murmur (ejection systolic murmur)
- Bounding pulse
- Signs of heart failure (if severe and chronic)
Thyroid Examination
Thyroid dysfunction is a common cause of menstrual abnormalities. Examine the thyroid gland systematically:
- Inspection — Visible swelling; ask patient to swallow
- Palpation — Size, consistency, nodularity, tenderness
- Signs of hypothyroidism — Dry skin, coarse hair, periorbital edema, bradycardia, delayed relaxation of reflexes
- Signs of hyperthyroidism — Tremor, warm moist skin, lid lag, tachycardia, hyperreflexia
Abdominal Examination
Inspection
- Abdominal distension — may indicate large fibroids or ascites
- Visible mass arising from pelvis
- Surgical scars — previous pelvic surgery
Palpation
- Pelvic mass — A fibroid uterus may be palpable abdominally if enlarged beyond 12 weeks’ gestational size
- Characteristics — Size, consistency (fibroids are firm), mobility, tenderness
- Upper border — Inability to palpate below a mass suggests pelvic origin
- Hepatomegaly — May indicate systemic disease affecting coagulation
- Splenomegaly — Consider hematological causes
Pelvic Examination
Before Pelvic Examination
Ensure the patient has emptied her bladder. Offer a chaperone and document their presence. Explain each step of the examination. Pelvic examination may be deferred in adolescents who are not sexually active if history is consistent with a benign cause.
External Genital Inspection
- Vulvar lesions, atrophy, or discharge
- Signs of infection
- Evidence of trauma
Speculum Examination
| Structure | What to Assess | Abnormal Findings |
|---|---|---|
| Vaginal walls | Atrophy, lesions, discharge | Atrophic changes (postmenopausal); vaginal lesions |
| Cervix | Position, appearance, lesions, discharge, bleeding source | Cervical polyp, ectropion, contact bleeding, suspicious lesion (requires biopsy) |
| Cervical os | Open or closed; any prolapsing tissue | Prolapsing fibroid or polyp through cervical os |
| Bleeding | Source of bleeding — cervical, uterine, or vaginal | Active bleeding; blood clots in vagina |
Bimanual Examination
| Finding | How to Assess | Clinical Significance |
|---|---|---|
| Uterine size | Compare to gestational weeks (normal is approximately 8 cm, “lemon-sized”) | Enlarged uterus suggests fibroids or adenomyosis; describe in weeks’ size |
| Uterine contour | Regular or irregular surface | Irregular, nodular surface suggests fibroids |
| Uterine consistency | Firm or soft | Diffusely enlarged, boggy, tender uterus suggests adenomyosis |
| Uterine mobility | Freely mobile or fixed | Fixed uterus suggests adhesions or endometriosis |
| Uterine tenderness | Pain on palpation or movement | Tenderness suggests adenomyosis, infection, or endometriosis |
| Adnexal masses | Palpate lateral to uterus bilaterally | Ovarian cyst, endometrioma, or tubal pathology |
| Cervical motion tenderness | Pain on moving cervix side to side | Suggests pelvic inflammatory disease or ectopic pregnancy |
Signs of Bleeding Disorders
If a coagulopathy is suspected, examine specifically for:
- Petechiae — Pinpoint hemorrhages suggesting platelet disorder
- Purpura — Larger areas of bleeding into skin
- Ecchymoses — Bruises, especially in unusual locations or without known trauma
- Mucosal bleeding — Gum bleeding, epistaxis
- Joint swelling — Hemarthrosis in severe factor deficiencies
Expected Findings by Etiology
| Condition | General Examination | Abdominal Examination | Pelvic Examination |
|---|---|---|---|
| Uterine fibroids | May be normal; pallor if anemic | Palpable mass if large (greater than 12 weeks’ size); firm, irregular | Enlarged, irregular, firm uterus; mobile unless complicated |
| Adenomyosis | Usually normal; pallor if anemic | Usually normal; may be mildly enlarged uterus palpable | Diffusely enlarged, globular, boggy, tender uterus |
| Endometrial polyp | Usually normal | Normal | Usually normal; polyp may be visible at cervical os |
| Ovulatory dysfunction (polycystic ovary syndrome) | Obesity, hirsutism, acne, acanthosis nigricans | Central obesity | Usually normal; may have enlarged ovaries |
| Coagulopathy | Bruising, petechiae, mucosal bleeding | Normal; possible hepatosplenomegaly | Usually normal |
| Hypothyroidism | Dry skin, coarse hair, periorbital edema, bradycardia, goiter | Normal | Usually normal |
| Endometrial malignancy | Often normal; may have pallor, weight loss | Usually normal; may have mass if advanced | May be normal; uterus may be enlarged; blood at cervical os |
Important Teaching Point
Normal examination is common! Many causes of heavy menstrual bleeding present with an entirely normal physical examination. Endometrial polyps, small fibroids, coagulopathies, ovulatory dysfunction, and primary endometrial hemostatic disorders often cannot be detected on clinical examination. A normal examination does not exclude significant pathology and should not delay appropriate investigation.
When to Perform Pelvic Examination
| Scenario | Recommendation | Rationale |
|---|---|---|
| Sexually active adult | Perform pelvic examination | Assess for structural abnormalities; obtain cervical samples if needed |
| Adolescent not sexually active | May defer if history suggests benign cause | Coagulopathy and anovulation common; pelvic examination traumatic and rarely changes management |
| Postmenopausal bleeding | Essential — perform pelvic examination | Must exclude malignancy; assess cervix and uterus |
| Acute severe bleeding | Perform after initial stabilization | Identify bleeding source; assess for cervical pathology; remove clots if present |
5. Differential Diagnosis
Systematic approach organized by the PALM-COEIN classification and clinical probability
The differential diagnosis of heavy menstrual bleeding is best organized using the FIGO PALM-COEIN classification system, which separates structural causes (PALM) from non-structural causes (COEIN). Within each category, conditions are further organized by probability based on age and clinical presentation. Remember that multiple causes may coexist in the same patient.
Structural Causes (PALM) — By Probability
| Probability | Condition | Key Features | Red Flags |
|---|---|---|---|
| COMMON (approximately 40-50%) | Uterine leiomyomas (fibroids) | Regular heavy periods; pelvic pressure; urinary frequency; enlarged irregular uterus on examination | Rapid growth; postmenopausal growth (consider leiomyosarcoma) |
| COMMON (approximately 20-35%) | Adenomyosis | Heavy painful periods; dysmenorrhea worsening with age; diffusely enlarged boggy tender uterus | Severe anemia; failure to respond to medical therapy |
| LESS COMMON (approximately 10-25%) | Endometrial polyps | Intermenstrual bleeding; postcoital bleeding; often asymptomatic; usually normal examination | Postmenopausal bleeding; polyp greater than 1.5 cm (increased malignancy risk) |
| UNCOMMON BUT SERIOUS (approximately 1-2%) | Endometrial hyperplasia | Irregular heavy bleeding; obesity; polycystic ovary syndrome; unopposed estrogen exposure | Atypia on histology (25% progress to carcinoma) |
| UNCOMMON BUT SERIOUS (approximately 1-2%) | Endometrial carcinoma | Postmenopausal bleeding; irregular bleeding in older women; risk factors: obesity, diabetes, nulliparity | Any postmenopausal bleeding; persistent abnormal bleeding over age 45 |
| RARE | Cervical malignancy | Postcoital bleeding; intermenstrual bleeding; abnormal discharge; visible cervical lesion | Any suspicious cervical lesion requires urgent referral and biopsy |
Non-Structural Causes (COEIN) — By Probability
| Probability | Condition | Key Features | Red Flags |
|---|---|---|---|
| COMMON (approximately 20-30%) | Ovulatory dysfunction | Irregular unpredictable cycles; obesity; hirsutism; extremes of reproductive age | Prolonged amenorrhea followed by heavy bleeding (hyperplasia risk) |
| COMMON (approximately 15-20%) | Endometrial hemostatic dysfunction | Regular heavy periods; no structural abnormality; normal coagulation studies; diagnosis of exclusion | Severe anemia despite treatment |
| LESS COMMON (approximately 10-20% in adolescents; 5-10% in adults) | Coagulopathy | Heavy periods since menarche; bleeding with surgery or dental work; easy bruising; family history | Acute severe bleeding with hemodynamic instability |
| LESS COMMON (approximately 5-10%) | Iatrogenic causes | Temporal relationship to medication initiation; anticoagulants; copper intrauterine device; hormonal breakthrough | Severe bleeding on anticoagulation |
| LESS COMMON | Thyroid dysfunction | Hypothyroidism: heavy prolonged periods; Hyperthyroidism: light or absent periods; systemic symptoms | Myxedema; thyroid storm features |
Age-Based Differential Approach
Step-by-Step Approach by Age Group:
- Adolescents (menarche to 19 years): First consider anovulation (immature hypothalamic-pituitary-ovarian axis) and coagulopathy (up to 20% have underlying bleeding disorder). Structural causes are rare.
- Reproductive age (20-39 years): Structural causes become more common — fibroids, adenomyosis, polyps. Also consider ovulatory dysfunction (polycystic ovary syndrome) and iatrogenic causes.
- Perimenopause (40-menopause): Anovulation is common; must exclude endometrial hyperplasia and malignancy in all women over 45 with abnormal bleeding.
- Postmenopause: Any bleeding requires investigation to exclude malignancy. Endometrial atrophy is the most common cause but is a diagnosis of exclusion.
| Age Group | Most Common Causes | Must Exclude | Key Investigations |
|---|---|---|---|
| Adolescents | Anovulation (most common), coagulopathy (up to 20%) | Bleeding disorders, pregnancy | Pregnancy test, coagulation screen, complete blood count |
| Reproductive age | Fibroids, adenomyosis, polyps, ovulatory dysfunction | Pregnancy, infection | Pregnancy test, ultrasound, consider hysteroscopy |
| Perimenopause | Anovulation, fibroids, adenomyosis, polyps | Endometrial hyperplasia, malignancy | Ultrasound, endometrial biopsy if over 45 or risk factors |
| Postmenopause | Endometrial atrophy, polyps | Endometrial carcinoma (10% of postmenopausal bleeding) | Transvaginal ultrasound, endometrial biopsy mandatory |
Anatomical Approach to Causes
Uterine Cavity
Endometrial polyps
Submucosal fibroids
Endometrial hyperplasia
Endometrial carcinoma
Endometritis
Intrauterine device
Myometrium
Intramural fibroids
Adenomyosis
Leiomyosarcoma (rare)
Cervix and Lower Tract
Cervical polyps
Cervical ectropion
Cervical malignancy
Vaginal lesions
Trauma
Systemic Causes
Coagulopathies (von Willebrand disease)
Platelet disorders
Thyroid dysfunction
Liver disease
Medications
Coagulopathies Causing Heavy Menstrual Bleeding
| Condition | Prevalence in Heavy Menstrual Bleeding | Key Features | Diagnostic Test |
|---|---|---|---|
| von Willebrand disease | 5-20% (most common inherited bleeding disorder) | Heavy periods since menarche; mucosal bleeding; family history; normal platelet count | von Willebrand factor antigen, ristocetin cofactor activity, factor VIII |
| Platelet function disorders | 1-5% | Easy bruising; prolonged bleeding from cuts; mucosal bleeding; normal platelet count | Platelet function analyzer (PFA-100); platelet aggregation studies |
| Thrombocytopenia | Variable | Petechiae; purpura; may be drug-induced, immune, or marrow-related | Complete blood count; peripheral smear; bone marrow if indicated |
| Factor deficiencies | Rare (carriers of hemophilia) | Factor XI deficiency more common in women; variable bleeding severity | Prothrombin time, activated partial thromboplastin time; specific factor assays |
Drug-Induced Heavy Menstrual Bleeding
| Drug or Drug Class | Mechanism | Characteristics | Management |
|---|---|---|---|
| Copper intrauterine device | Increases prostaglandin synthesis; foreign body inflammatory response | 20-50% increase in menstrual blood loss; usually improves after first year | Trial of tranexamic acid or NSAIDs; consider removal if severe |
| Anticoagulants (warfarin, direct oral anticoagulants) | Impaired coagulation cascade | Increased bleeding with therapeutic anticoagulation; dose-related | Review indication; tranexamic acid may help; hormonal suppression |
| Antiplatelet agents (aspirin, clopidogrel) | Inhibition of platelet aggregation | Prolonged bleeding; may unmask underlying bleeding tendency | Review necessity; consider alternatives if possible |
| Selective serotonin reuptake inhibitors | Reduced platelet serotonin uptake impairs aggregation | Mild increase in bleeding; may be significant with other risk factors | Usually continue; treat symptomatically |
| Tamoxifen | Estrogenic effect on endometrium; promotes polyps and hyperplasia | Any bleeding on tamoxifen requires investigation | Endometrial assessment; hysteroscopy; oncology review |
| Progestogen-only contraception (initial use) | Endometrial instability during adjustment period | Irregular bleeding common in first 3-6 months; usually settles | Counseling; short course of estrogen may help; persistence usually resolves |
| Corticosteroids (long-term) | Affects vascular integrity; may affect coagulation | Variable effect on menstrual bleeding | Address underlying condition; treat symptomatically |
| Herbal supplements (ginkgo, garlic, ginseng, fish oil) | Antiplatelet effects; affects coagulation factors | Often not reported by patients; cumulative effect with other agents | Detailed medication history; trial of discontinuation |
Quick Reference: “If You See This, Think This”
| Clinical Clue | Think This First | Next Step |
|---|---|---|
| Heavy periods since menarche + easy bruising + family history | von Willebrand disease or other coagulopathy | Coagulation screen; von Willebrand panel; hematology referral |
| Regular heavy periods + enlarged irregular firm uterus | Uterine fibroids | Pelvic ultrasound; assess fibroid location |
| Heavy painful periods + diffusely enlarged boggy tender uterus | Adenomyosis | Transvaginal ultrasound; MRI if uncertain |
| Irregular cycles + obesity + hirsutism + acne | Polycystic ovary syndrome with anovulation | Hormone profile; ultrasound; assess for metabolic syndrome |
| Intermenstrual or postcoital bleeding | Cervical or endometrial polyp; cervical pathology | Speculum examination; cervical screening; ultrasound; hysteroscopy |
| Any bleeding after menopause | Endometrial pathology — must exclude malignancy | Urgent transvaginal ultrasound; endometrial biopsy |
| Bleeding started after copper intrauterine device insertion | Copper intrauterine device-related bleeding | Trial of tranexamic acid or NSAIDs; consider alternative contraception |
| Heavy bleeding + on anticoagulation | Anticoagulant-related bleeding | Check therapeutic levels; tranexamic acid; hormonal suppression; hematology input |
| Adolescent with heavy periods since menarche | Anovulation or coagulopathy | Exclude pregnancy; coagulation screen; trial of hormonal therapy |
| Heavy periods + fatigue + thyroid symptoms | Hypothyroidism | Thyroid function tests |
6. Diagnostic Investigations
A stepwise, cost-effective approach guided by clinical suspicion
Investigation of heavy menstrual bleeding should be guided by clinical findings and tailored to the patient’s age and risk factors. Not all patients require extensive investigation — young women with regular cycles and no red flags may be treated empirically. However, women over 45, those with risk factors for endometrial pathology, or those failing initial treatment require more thorough evaluation.
Baseline Investigations for All Patients
| Investigation | Purpose | What to Look For | Practical Points |
|---|---|---|---|
| Complete blood count | Assess for anemia; evaluate platelet count | Hemoglobin less than 120 g/L indicates anemia; microcytic indices suggest iron deficiency; thrombocytopenia | Essential in all patients; guides urgency of treatment |
| Ferritin | Assess iron stores | Ferritin less than 30 μg/L confirms iron deficiency; may be falsely elevated in inflammation | More sensitive than hemoglobin for early iron depletion |
| Pregnancy test (urine or serum beta-hCG) | Exclude pregnancy in reproductive-age women | Positive test requires urgent evaluation for pregnancy complications | Mandatory before initiating hormonal treatment or procedures |
| Thyroid function tests (TSH) | Screen for thyroid dysfunction | Elevated TSH indicates hypothyroidism; suppressed TSH suggests hyperthyroidism | Cost-effective screening test; order free T4 if TSH abnormal |
Coagulation Studies — When to Order
Indications for Coagulation Screening
Order coagulation studies if any of the following are present:
- Heavy menstrual bleeding since menarche
- Personal history of bleeding with surgery, dental procedures, or childbirth
- Easy bruising or prolonged bleeding from minor cuts
- Family history of bleeding disorder
- Adolescent presenting with heavy menstrual bleeding (screen all)
- Acute heavy bleeding requiring hospitalization
| Test | What It Assesses | Abnormal Result Suggests |
|---|---|---|
| Prothrombin time (PT) / INR | Extrinsic pathway and common pathway | Factor VII deficiency; warfarin effect; liver disease |
| Activated partial thromboplastin time (aPTT) | Intrinsic pathway and common pathway | Factor VIII, IX, XI deficiency; von Willebrand disease; heparin effect |
| Platelet count | Number of platelets | Thrombocytopenia (less than 150 × 10⁹/L) |
| von Willebrand factor antigen | Amount of von Willebrand factor protein | Reduced in von Willebrand disease |
| Ristocetin cofactor activity | Function of von Willebrand factor | Reduced in von Willebrand disease |
| Factor VIII level | Factor VIII concentration | Reduced in von Willebrand disease and hemophilia A carriers |
Imaging Investigations
Transvaginal Ultrasound — First-Line Imaging
When to Order
- Pelvic mass suspected or palpated
- Failed initial medical treatment
- Symptoms suggesting structural pathology
- Women over 45 with abnormal bleeding
- Any postmenopausal bleeding
- Before considering surgical intervention
What It Can Identify
- Uterine fibroids — number, size, location
- Adenomyosis — asymmetry, heterogeneous myometrium, cysts
- Endometrial polyps — focal thickening, single feeding vessel
- Endometrial thickness — thin endometrium (less than 4-5 mm) has high negative predictive value for pathology
- Ovarian pathology
| Ultrasound Finding | Description | Clinical Significance |
|---|---|---|
| Endometrial thickness greater than 4 mm (postmenopausal) | Thickened endometrial stripe | Requires endometrial sampling to exclude hyperplasia or malignancy |
| Submucosal fibroid | Fibroid distorting or protruding into endometrial cavity | Most likely to cause heavy bleeding; may require hysteroscopic resection |
| Heterogeneous myometrium with cysts | Diffuse myometrial abnormality; myometrial cysts | Suggestive of adenomyosis |
| Focal endometrial lesion with feeding vessel | Discrete lesion within endometrial cavity with single vessel on Doppler | Suggestive of endometrial polyp |
| Intrauterine device in situ | Echogenic structure within cavity | Confirm correct position; malposition may contribute to bleeding |
Additional Imaging Modalities
| Imaging Modality | Indication | Advantages | Limitations |
|---|---|---|---|
| Saline infusion sonohysterography | Better delineation of intrauterine pathology; pre-operative planning | Excellent for polyps and submucosal fibroids; outpatient procedure | Requires expertise; may cause discomfort; cannot be done if active bleeding or infection |
| Pelvic MRI | Fibroid mapping pre-surgery; adenomyosis confirmation; complex cases | Best for adenomyosis diagnosis; accurate fibroid mapping; no radiation | Expensive; not always necessary; limited availability |
| Hysteroscopy | Direct visualization of uterine cavity; simultaneous diagnosis and treatment | Gold standard for intrauterine pathology; allows biopsy and resection | Invasive; requires specialized equipment and training |
Endometrial Sampling
Mandatory Indications for Endometrial Biopsy
- Any postmenopausal bleeding — regardless of ultrasound findings
- Women over 45 with abnormal uterine bleeding
- Women under 45 with risk factors: obesity (BMI greater than 30), polycystic ovary syndrome, chronic anovulation, diabetes, tamoxifen use, family history of endometrial or colorectal cancer
- Persistent abnormal bleeding despite treatment
- Thickened endometrium on ultrasound (greater than 4 mm postmenopausal; greater than 12 mm premenopausal)
| Method | Description | When to Use | Limitations |
|---|---|---|---|
| Pipelle endometrial biopsy | Office-based suction biopsy using thin plastic catheter | First-line for endometrial sampling; screening for hyperplasia and malignancy | Samples only 4-10% of cavity; may miss focal lesions; sensitivity 91% for cancer |
| Hysteroscopy with directed biopsy | Direct visualization with targeted sampling | Focal lesions seen on ultrasound; failed or inadequate Pipelle; polyp removal | More invasive; requires equipment and expertise |
| Dilatation and curettage | Cervical dilatation with uterine curettage | Acute heavy bleeding for hemostasis; when other methods fail; therapeutic | Requires anesthesia; still may miss focal lesions; rarely diagnostic alone |
Targeted Investigations by Suspected Etiology
If Suspecting Ovulatory Dysfunction
First-Line Tests
- Day 21 progesterone (or 7 days before expected period): Level greater than 30 nmol/L confirms ovulation
- TSH: Thyroid dysfunction causes menstrual irregularity
- Prolactin: Hyperprolactinemia causes anovulation
Second-Line Tests (if polycystic ovary syndrome suspected)
- LH, FSH, estradiol: LH:FSH ratio may be elevated
- Free testosterone, SHBG: Elevated androgens
- Fasting glucose, HbA1c: Screen for diabetes
- Lipid profile: Metabolic syndrome assessment
If Suspecting Coagulopathy
Initial Coagulation Screen
- Complete blood count with platelet count
- Prothrombin time (PT/INR)
- Activated partial thromboplastin time (aPTT)
- Fibrinogen
von Willebrand Disease Panel
- von Willebrand factor antigen
- Ristocetin cofactor activity
- Factor VIII level
- Note: Levels vary with menstrual cycle, stress, and inflammation; may need to repeat if borderline
If Suspecting Structural Pathology
| Suspected Condition | First-Line Investigation | Second-Line Investigation | Key Findings |
|---|---|---|---|
| Uterine fibroids | Transvaginal ultrasound | MRI (for surgical planning); saline infusion sonohysterography | Number, size, location (submucosal, intramural, subserosal); FIGO classification |
| Adenomyosis | Transvaginal ultrasound | MRI (definitive diagnosis) | Asymmetric uterine enlargement; heterogeneous myometrium; myometrial cysts; junctional zone thickening on MRI |
| Endometrial polyp | Transvaginal ultrasound | Saline infusion sonohysterography; hysteroscopy | Focal endometrial thickening; single feeding vessel on Doppler |
| Endometrial hyperplasia or malignancy | Transvaginal ultrasound + endometrial biopsy | Hysteroscopy with directed biopsy; CT or MRI for staging if malignancy confirmed | Thickened endometrium; histological diagnosis essential |
Empiric Treatment Trials as Diagnostic Tools
When Empiric Treatment is Appropriate
In young women (under 40) with regular heavy menstrual bleeding, no red flags, and no risk factors for endometrial pathology, empiric medical treatment may be initiated without extensive investigation. Response to therapy supports a diagnosis of primary endometrial hemostatic dysfunction. However, failure to respond should prompt further investigation.
- Trial 1: Tranexamic acid or nonsteroidal anti-inflammatory drugs for 3 cycles — tests for primary hemostatic dysfunction
- Trial 2: Combined hormonal contraception or cyclical progestogens for 3 cycles — tests for ovulatory dysfunction component
- Trial 3: Levonorgestrel intrauterine system for 6 months — highly effective; diagnostic if bleeding resolves
If bleeding persists after adequate trials: Proceed to transvaginal ultrasound, endometrial biopsy (if over 45 or risk factors), and hysteroscopy to exclude structural pathology.
Investigation Pathway Summary
Minimum Investigations for All Patients:
- Complete blood count and ferritin
- Pregnancy test (reproductive age)
- Consider TSH
Add Coagulation Screen if: Heavy bleeding since menarche, personal or family bleeding history, adolescent
Add Pelvic Ultrasound if: Suspected structural pathology, failed medical treatment, age over 40
Add Endometrial Biopsy if: Age over 45, postmenopausal, risk factors for endometrial hyperplasia or malignancy, thickened endometrium, persistent bleeding despite treatment
7. Pattern Recognition and Clinical Decision-Making
Practical algorithms and decision pathways
Step 1: Is This Urgent?
| Clinical Scenario | Urgency Level | Immediate Action |
|---|---|---|
| Hemodynamic instability (tachycardia, hypotension, syncope) | EMERGENT | Resuscitate; IV access; crossmatch blood; urgent gynecology consultation; consider transfusion; hormonal or surgical hemostasis |
| Severe anemia (hemoglobin less than 70 g/L) with active bleeding | EMERGENT | Admit; transfuse; high-dose hormonal therapy; consider procedural intervention |
| Postmenopausal bleeding | URGENT | Urgent referral; transvaginal ultrasound and endometrial biopsy within 2 weeks to exclude malignancy |
| Suspected pregnancy with bleeding | URGENT | Confirm pregnancy; ultrasound to determine viability and location; exclude ectopic pregnancy |
| Moderate anemia (hemoglobin 70-100 g/L) without active heavy bleeding | URGENT | Start iron replacement; initiate medical treatment; arrange investigations within 2-4 weeks |
| Heavy menstrual bleeding without anemia or red flags | ROUTINE | Elective investigation and treatment; can trial empiric medical therapy; routine referral if needed |
Step 2: Classify by Age Group
Adolescent (Menarche to 19)
Proceed to Algorithm A
Key considerations: Anovulation common; screen for coagulopathy; structural causes rare
Reproductive Age (20-45)
Proceed to Algorithm B
Key considerations: Full differential; structural causes common; exclude pregnancy
Perimenopausal and Postmenopausal (Over 45)
Proceed to Algorithm C
Key considerations: Must exclude malignancy; endometrial biopsy indicated
Step 3: Follow the Appropriate Algorithm
Algorithm A: Adolescent with Heavy Menstrual Bleeding
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Irregular heavy periods within 2 years of menarche; no bleeding symptoms elsewhere | Anovulation due to immature hypothalamic-pituitary-ovarian axis | Check CBC, ferritin; reassure; consider combined hormonal contraception or cyclic progestogens if bothersome |
| Heavy periods since menarche; easy bruising; epistaxis; family history of bleeding | Underlying coagulopathy (von Willebrand disease most common) | Full coagulation screen including von Willebrand panel; hematology referral; tranexamic acid; hormonal therapy |
| Acute severe bleeding at menarche or shortly after | Coagulopathy until proven otherwise | Admit if hemodynamically unstable; coagulation studies; high-dose estrogen or combined pill for acute hemostasis; transfuse if needed |
| Irregular periods with obesity, hirsutism, acne | Polycystic ovary syndrome with anovulation | Hormone profile; ultrasound; lifestyle modification; combined hormonal contraception |
Algorithm B: Reproductive Age Woman with Heavy Menstrual Bleeding
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Regular heavy periods; enlarged irregular firm uterus | Uterine fibroids | Pelvic ultrasound; if submucosal — refer for hysteroscopic resection; if not — trial medical therapy (levonorgestrel intrauterine system, tranexamic acid); consider surgical options if fails |
| Regular heavy painful periods; diffusely enlarged boggy tender uterus | Adenomyosis | Ultrasound (MRI if uncertain); levonorgestrel intrauterine system first-line; if fails and family complete — hysterectomy |
| Intermenstrual or postcoital bleeding; normal-sized uterus | Endometrial or cervical polyp | Speculum examination; ultrasound; hysteroscopy with polypectomy |
| Irregular heavy bleeding; obesity; signs of androgen excess | Polycystic ovary syndrome with anovulation | Exclude pregnancy; hormone profile; ultrasound; if over 45 or prolonged amenorrhea — endometrial biopsy; combined hormonal contraception or cyclic progestogens |
| Regular heavy periods; normal examination; no structural abnormality on imaging | Primary endometrial hemostatic dysfunction | Trial tranexamic acid or NSAIDs; if ineffective — levonorgestrel intrauterine system; consider coagulation screen if not done |
| Heavy bleeding started after copper intrauterine device insertion | Copper intrauterine device-related bleeding | Confirm correct position on ultrasound; trial tranexamic acid and NSAIDs; if persistent — discuss removal and alternative contraception |
Algorithm C: Perimenopausal or Postmenopausal Woman with Abnormal Bleeding
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Any bleeding after 12 months of amenorrhea (postmenopausal) | Must exclude endometrial malignancy (present in approximately 10%) | Urgent transvaginal ultrasound; endometrial biopsy mandatory regardless of endometrial thickness; refer to gynecology |
| Perimenopausal irregular heavy bleeding; endometrium thin on ultrasound | Anovulatory bleeding | Endometrial biopsy if over 45; hormonal regulation with progestogens or combined hormonal contraception (if no contraindications); levonorgestrel intrauterine system |
| Postmenopausal bleeding; endometrial thickness less than 4 mm | Endometrial atrophy (most common) | Endometrial biopsy still recommended; if benign — reassure; topical vaginal estrogen if atrophic vaginitis contributing |
| Postmenopausal bleeding; endometrial thickness greater than 4 mm or focal lesion | Polyp, hyperplasia, or malignancy | Urgent endometrial biopsy; hysteroscopy if focal lesion; refer to gynecologic oncology if malignancy confirmed |
| Bleeding on hormone replacement therapy | Breakthrough bleeding; exclude endometrial pathology | Review hormone replacement therapy regimen; ultrasound; endometrial biopsy if persistent or abnormal findings |
“What Do I Do If…” Decision Reference
| Clinical Situation | Immediate Action | Next Step |
|---|---|---|
| Acute heavy bleeding with hemodynamic instability | ABC approach; IV access × 2; fluid resuscitation; crossmatch; urgent gynecology consult | High-dose IV estrogen or high-dose combined oral contraceptive; transfuse if hemoglobin less than 70 g/L; consider intrauterine balloon tamponade or surgical intervention |
| Patient on anticoagulation with heavy menstrual bleeding | Check INR or drug levels; assess bleeding severity; do not stop anticoagulation without discussion with prescribing team | Tranexamic acid (caution — discuss with hematology); hormonal suppression with levonorgestrel intrauterine system or continuous combined hormonal contraception; consider anticoagulation review |
| Hemoglobin less than 70 g/L with ongoing bleeding | Admit; transfuse packed red blood cells; initiate hormonal hemostasis | Iron infusion once bleeding controlled; investigate cause; definitive treatment plan |
| Failed first-line medical treatment | Confirm compliance; review diagnosis; arrange pelvic ultrasound if not done | Try alternative medical therapy; if levonorgestrel intrauterine system not tried — insert; consider hysteroscopy to exclude missed pathology; discuss surgical options |
| Adolescent with acute severe menorrhagia at menarche | Assume coagulopathy until proven otherwise; admit if unstable; send urgent coagulation studies | High-dose hormonal therapy; transfuse if needed; hematology involvement; avoid NSAIDs until coagulopathy excluded |
| Patient desires fertility | Avoid treatments that affect fertility (endometrial ablation, hysterectomy) | Medical management (tranexamic acid, NSAIDs, short-term hormonal); treat underlying cause; myomectomy rather than hysterectomy for fibroids |
| Patient desires no more children and wants definitive treatment | Discuss surgical options | Endometrial ablation if normal cavity; hysterectomy for definitive management; levonorgestrel intrauterine system as intermediate option |
Medical Treatment Selection Guide
| Treatment | Best For | Avoid If | Expected Reduction in Blood Loss |
|---|---|---|---|
| Levonorgestrel intrauterine system | Most causes of heavy menstrual bleeding; adenomyosis; contraception also needed; long-term management | Active pelvic infection; distorted cavity preventing insertion; current breast cancer | 71-96% reduction; amenorrhea in 20-80% |
| Tranexamic acid | Primary hemostatic dysfunction; coagulopathy; use with copper intrauterine device; as-needed treatment | Active thromboembolic disease; history of venous thromboembolism (relative); renal impairment (dose reduce) | 40-50% reduction |
| Nonsteroidal anti-inflammatory drugs (mefenamic acid, naproxen) | Primary hemostatic dysfunction; dysmenorrhea; copper intrauterine device; short-term use | Peptic ulcer disease; aspirin-sensitive asthma; renal impairment; coagulopathy (may worsen) | 20-50% reduction |
| Combined hormonal contraception | Anovulatory bleeding; contraception needed; dysmenorrhea; can use continuously | Venous thromboembolism risk factors; migraine with aura; smoker over 35; breast cancer | 40-50% reduction |
| Cyclical progestogens (days 5-26) | Anovulatory bleeding; irregular cycles; endometrial protection | Less effective for ovulatory heavy menstrual bleeding; breast cancer | Variable; regularizes cycles |
| GnRH agonists (with add-back) | Pre-operative fibroid shrinkage; severe anemia needing correction; short-term use only | Long-term use (bone loss); not for ongoing management | Near amenorrhea; fibroid shrinkage 30-50% |
Troubleshooting Refractory Heavy Menstrual Bleeding
Ask These Questions When Treatment Fails
- Was the treatment duration adequate? — Levonorgestrel intrauterine system needs 6 months; medical therapy needs 3 cycles minimum
- Was patient compliance good? — Tranexamic acid must be taken regularly during menses; hormones must be taken as prescribed
- Is the levonorgestrel intrauterine system correctly positioned? — Check with ultrasound; expulsion or malposition reduces efficacy
- Is the diagnosis correct? — Review for missed structural pathology; consider hysteroscopy
- Are there multiple overlapping causes? — Fibroids plus adenomyosis; structural plus coagulopathy
- Has a coagulopathy been excluded? — Especially if bleeding since menarche or other bleeding symptoms
- Has endometrial pathology been excluded? — Endometrial biopsy if over 45 or risk factors
8. Clinical Pearls and Pitfalls
Practical wisdom — learn from successes and avoid common mistakes
Must-Know Clinical Pearls
Use the patient-centered definition: Heavy menstrual bleeding is bleeding that interferes with quality of life — the 80 mL threshold is impractical clinically. If the patient says it’s heavy and it’s affecting her life, it warrants evaluation and treatment.
Screen adolescents for coagulopathy: Up to 20% of adolescents presenting with heavy menstrual bleeding have an underlying bleeding disorder, most commonly von Willebrand disease. Always ask about bleeding since menarche, easy bruising, and family history.
Levonorgestrel intrauterine system is highly effective: The levonorgestrel intrauterine system reduces menstrual blood loss by over 90% and is first-line treatment for most causes of heavy menstrual bleeding. It is effective for fibroids, adenomyosis, and primary hemostatic dysfunction.
Fibroid location matters more than size: A small submucosal fibroid can cause severe bleeding while a large subserosal fibroid may cause none. Always determine fibroid location (FIGO classification) to guide management.
Treat iron deficiency even without anemia: Ferritin less than 30 μg/L indicates depleted iron stores. Women with heavy menstrual bleeding often have iron deficiency before hemoglobin drops — treating iron deficiency improves fatigue and quality of life.
Multiple causes often coexist: A woman may have fibroids AND adenomyosis AND a coagulopathy. If treatment targeting one cause fails, look for additional contributing factors.
Tranexamic acid works for many causes: As an antifibrinolytic, tranexamic acid is effective regardless of the underlying cause of heavy menstrual bleeding and can be used alongside other treatments. It is safe with hormonal therapy.
Empiric treatment is appropriate in young women: In women under 40 with regular heavy periods, no red flags, and no risk factors for endometrial pathology, empiric medical treatment without extensive investigation is reasonable.
Critical Pitfalls to Avoid
Missing postmenopausal bleeding as urgent: Any bleeding after 12 months of amenorrhea requires urgent investigation to exclude endometrial malignancy — present in approximately 10% of cases. Never attribute postmenopausal bleeding to “hormonal changes” without investigation.
Forgetting to exclude pregnancy: Always perform a pregnancy test in reproductive-age women before initiating treatment or performing procedures. Pregnancy complications (ectopic, miscarriage) can present as heavy bleeding.
Not checking coagulation in adolescents: Heavy menstrual bleeding since menarche should prompt coagulation screening. Missing von Willebrand disease means missing opportunities for targeted treatment and counseling before surgery or pregnancy.
Assuming normal examination excludes pathology: Many causes of heavy menstrual bleeding (polyps, small fibroids, coagulopathies, adenomyosis) have completely normal physical examination findings. A normal examination does not rule out significant disease.
Relying on dilatation and curettage alone for diagnosis: Dilatation and curettage samples only a portion of the endometrium and can miss focal lesions like polyps. Hysteroscopy is superior for evaluating the uterine cavity.
Using NSAIDs when coagulopathy is suspected: Nonsteroidal anti-inflammatory drugs impair platelet function and can worsen bleeding in women with von Willebrand disease or platelet disorders. Exclude coagulopathy before recommending NSAIDs for heavy menstrual bleeding since menarche.
Inadequate treatment duration before declaring failure: The levonorgestrel intrauterine system needs 6 months for full effect — irregular bleeding in the first 3-6 months is expected. Medical treatments need at least 3 cycles to assess efficacy.
Ignoring medication history: Always ask about anticoagulants, antiplatelet agents, copper intrauterine device, tamoxifen, and herbal supplements. Iatrogenic causes are common and treatable.
Key Takeaways
- Heavy menstrual bleeding is defined by impact on quality of life, not by measured blood loss — if it’s affecting her life, it warrants attention.
- Use PALM-COEIN to systematically consider all causes: Polyp, Adenomyosis, Leiomyoma, Malignancy — Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not classified.
- Age determines the differential: adolescents — think anovulation and coagulopathy; reproductive age — think structural causes; over 45 — must exclude malignancy.
- Screen all adolescents with heavy menstrual bleeding for coagulopathy — up to 20% have an underlying bleeding disorder.
- Postmenopausal bleeding requires urgent investigation regardless of risk factors — endometrial malignancy is present in approximately 10% of cases.
- The levonorgestrel intrauterine system is first-line treatment for most causes of heavy menstrual bleeding, reducing blood loss by over 90%.
- Normal physical examination is common and does not exclude significant pathology — imaging and histology are often needed.
- Multiple causes frequently coexist — if treatment fails, look for additional contributing factors.
- Treat iron deficiency (ferritin less than 30 μg/L) even before anemia develops to improve symptoms.
- Always exclude pregnancy in reproductive-age women before investigation or treatment.
Quick Reference Algorithm
Systematic Approach to Heavy Menstrual Bleeding:
- Assess urgency: Is the patient hemodynamically stable? Is there severe anemia? Is this postmenopausal bleeding?
- Take a focused history: Use the “HEAVY” mnemonic — How much, Evolution, Associated symptoms, Vital background, Your life impact
- Identify red flags: Postmenopausal bleeding, intermenstrual bleeding over age 45, hemodynamic instability, symptoms of severe anemia
- Perform examination: General (pallor, thyroid, bruising), abdominal, pelvic (speculum and bimanual)
- Order baseline investigations: Complete blood count, ferritin, pregnancy test (if reproductive age), TSH; coagulation screen if indicated
- Image if indicated: Transvaginal ultrasound for suspected structural pathology, failed treatment, or age over 40
- Sample endometrium if indicated: All postmenopausal bleeding; women over 45 with abnormal bleeding; risk factors for hyperplasia or malignancy
- Treat based on cause and patient preferences: Consider fertility wishes, contraception needs, and patient goals when selecting treatment
- Follow up: Reassess response; adjust treatment; investigate further if not responding